Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine dose-ranging placebo-controlled study in outpatients with major depressive disorder
ISRCTN10845256Phase 3Completed
- Sponsor
- Servier
- Start
- Oct 2009
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of agomelatine in major depressive disorder (MDD) (4 arms), sponsored by Servier. Primary endpoint: HAM-D total score change. Started Oct 2009; status: completed.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ISRCTN10845256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10845256.